---
title: "Biocytogen Calls 2026 Extraordinary Meeting to Vote on New Non-Executive Director"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/273868400.md"
description: "Biocytogen Pharmaceuticals (Beijing) Co. Ltd. has announced an extraordinary general meeting on February 12, 2026, to vote on the appointment of Mr. Liu Hongkang as a non-executive director. The meeting will be held in a hybrid format to enhance shareholder participation. This decision may influence the company's board composition and governance. The current analyst rating for Biocytogen's stock (HK:2315) is a Hold, with a price target of HK$48.00 and a market cap of HK$16.99B."
datetime: "2026-01-27T14:40:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273868400.md)
  - [en](https://longbridge.com/en/news/273868400.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273868400.md)
---

# Biocytogen Calls 2026 Extraordinary Meeting to Vote on New Non-Executive Director

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H ( (HK:2315) ) has issued an announcement.

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has called its first extraordinary general meeting of 2026 for 12 February in a hybrid format, combining a physical meeting in Beijing with an online e-meeting system to allow broader shareholder participation. Shareholders will vote on the proposed appointment of Mr. Liu Hongkang as a non-executive director, a move that could further shape the company’s board composition and corporate governance, with detailed procedures laid out for H shareholders and non-registered holders to attend, vote, and appoint proxies ahead of the meeting.

The most recent analyst rating on (HK:2315) stock is a Hold with a HK$48.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.

**More about Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H**

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a PRC-incorporated biopharmaceutical company listed in Hong Kong (Stock Code: 2315), operating in the biotechnology and pharmaceutical industry with a focus on drug discovery and development. The company is governed by a board comprising executive, non-executive, independent non-executive and employee directors, reflecting a typical listed-company governance structure in the Hong Kong market.

**Average Trading Volume:** 1,465,713

**Technical Sentiment Signal:** Hold

**Current Market Cap:** HK$16.99B

### Related Stocks

- [688796.CN](https://longbridge.com/en/quote/688796.CN.md)

## Related News & Research

- [Finsbury Growth & Income Trust Director Reinvests Dividends into Company Shares](https://longbridge.com/en/news/286940848.md)
- [REI directors boost stakes as Midlands REIT advances portfolio sell-down](https://longbridge.com/en/news/286902533.md)
- [Netcall discloses share sale by non-executive director Michael Jackson](https://longbridge.com/en/news/286431477.md)
- [Foxconn Industrial Internet Sets June 2025 Shareholders’ Meeting With Focus on Dividends and Governance](https://longbridge.com/en/news/286894210.md)
- [21:15 ETAutonomous AI marketing platform Protaigé launches with Maia, the world's first AI Account Director that operates within the flow of work](https://longbridge.com/en/news/286985056.md)